Video

Dr. Gandara on the Utility of TMB in NSCLC

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care® in Lung Cancer, discusses the utility of tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC).

​Along with PD-L1​, recent data suggest that TMB is another predictive biomarker for checkpoint inhibitors, says Gandara. However, TMB varies significantly between different cancer types and within individual patients, making TMB a complex biomarker.

​Recently, pembrolizumab (Keytruda) received its second biomarker-based indication from the FDA for adult and pediatric patients with unresectable or metastatic TMB-high solid tumors. According to Gandara, while this approval is a step forward in this space, it raises questions that need to be answered.

Notably, NSCLC is associated with a high mutational burden compared with other cancers as many patients were former smokers. As such, TMB may have many implications regarding the use of immunotherapy in NSCLC, Gandara concludes.

Related Videos
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.